[Asia Economy Reporter Hyunseok Yoo] Access Bio announced on the 6th that its COVID-19 antigen diagnostic products can detect the Omicron variant of COVID-19.
According to recent in-silico analysis conducted by Access Bio, the protein sequence of the Omicron variant virus disclosed by the Global Initiative on Sharing All Influenza Data (GISAID) does not affect the target (nucleocapsid protein) of the company's products.
Additionally, antigen-antibody tests using recombinant antigen were conducted. It was confirmed that all variant viruses designated as variants of concern by the World Health Organization (WHO), including Omicron, Alpha, Beta, Gamma, and Delta, can be diagnosed.
Access Bio's main COVID-19 antigen products are the CareStartTM COVID-19 Antigen test and CareStartTM COVID-19 Home test, which are produced in the United States. Currently, most of these products are being sold out in the U.S. market. Therefore, it is expected that efforts to diversify markets will accelerate overseas market entry in the future.
Choi Young-ho, CEO of Access Bio, stated, "Based on the excellent competitiveness of our products verified by the U.S. FDA, the short-term challenge we need to solve is how to efficiently produce the incoming orders and meet the market's demand for rapid delivery." He added, "To address this, the company is negotiating with multiple CMOs and focusing on improving its own production capacity."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
